Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M, Hijmans EM, Gennissen AMC, Wong NKY, Li S, Wisman GBA, Hamilton A, Hoenisch J, Dawson A, Lee CH, Bittner M, Kim H, DiMattia GE, Lok CAR, Lieftink C, Beijersbergen RL, de Jong S, Carey MS, Bernards R, Berns K. Llaurado Fernandez M, et al. Among authors: hoenisch j. Mol Cancer Ther. 2022 Dec 2;21(12):1862-1874. doi: 10.1158/1535-7163.MCT-22-0004. Mol Cancer Ther. 2022. PMID: 36198031 Free PMC article.
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.
Cheasley D, Fernandez ML, Köbel M, Kim H, Dawson A, Hoenisch J, Bittner M, Chiu DS, Talhouk A, Gilks CB, Jayawardana MW, Pishas KI, Mes-Masson AM, Provencher D, Nigam A, Hacker NF, Gorringe KL, Campbell IG, Carey MS. Cheasley D, et al. Among authors: hoenisch j. NPJ Precis Oncol. 2022 Jun 29;6(1):47. doi: 10.1038/s41698-022-00288-2. NPJ Precis Oncol. 2022. PMID: 35768582 Free PMC article.
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R, Llaurado Fernandez M, Dawson A, Hoenisch J, Volik S, Lin YY, Anderson S, Kim H, Haegert AM, Colborne S, Wong NKY, McConeghy B, Bell RH, Brahmbhatt S, Lee CH, DiMattia GE, Le Bihan S, Morin GB, Collins CC, Carey MS. Shrestha R, et al. Among authors: hoenisch j. Cancer Res. 2021 Apr 1;81(7):1681-1694. doi: 10.1158/0008-5472.CAN-20-2222. Epub 2021 Jan 13. Cancer Res. 2021. PMID: 33441310
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M, Dawson A, Kim H, Lam N, Russell H, Bruce M, Bittner M, Hoenisch J, Scott SA, Talhouk A, Chiu D, Provencher D, Nourmoussavi M, DiMattia G, Lee CH, Gilks CB, Köbel M, Carey MS. Llaurado Fernandez M, et al. Among authors: hoenisch j. Gynecol Oncol. 2020 Apr;157(1):12-20. doi: 10.1016/j.ygyno.2019.11.029. Epub 2020 Jan 15. Gynecol Oncol. 2020. PMID: 31954537
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML, Dawson A, Hoenisch J, Kim H, Bamford S, Salamanca C, DiMattia G, Shepherd T, Cremona M, Hennessy B, Anderson S, Volik S, Collins CC, Huntsman DG, Carey MS. Fernandez ML, et al. Among authors: hoenisch j. Cancer Cell Int. 2019 Jan 8;19:10. doi: 10.1186/s12935-019-0725-1. eCollection 2019. Cancer Cell Int. 2019. PMID: 30636931 Free PMC article.